Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q4 FY25 results · Jan–Mar 2025
Solara Active Pharma Sciences reported revenue from operations of ₹273.01 crore (down 8.8% from Q4 FY24) and net loss of ₹2.10 crore for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 273.01 | 299.43 | −8.8% | 300.31 | −9.1% |
| Other income | 5.95 | 1.70 | +250.0% | 1.49 | +299.3% |
| Total income | 278.96 | 301.13 | −7.4% | 301.80 | −7.6% |
| Profit before tax | (2.10) | (166.66) | Loss narrowed | 8.09 | Turned loss |
| Net profit for the period | (2.10) | (255.45) | Loss narrowed | 8.09 | Turned loss |
| EPS, basic (₹) | (0.93) | (70.93) | not comparable | 2.03 | Turned loss |
| Net margin (%) | -0.8 | -85.3 | 2.7 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 273.01 | 299.43 | −8.8% | 300.31 | −9.1% |
| Other income | 5.95 | 1.63 | +265.0% | 1.49 | +299.3% |
| Total income | 278.96 | 301.06 | −7.3% | 301.80 | −7.6% |
| Profit before tax | (4.88) | (167.62) | Loss narrowed | 8.10 | Turned loss |
| Net profit for the period | (4.88) | (256.41) | Loss narrowed | 8.10 | Turned loss |
| EPS, basic (₹) | (1.65) | (71.23) | not comparable | 2.47 | Turned loss |
| Net margin (%) | -1.8 | -85.6 | 2.7 |
Consolidated
- Filed with BSE
- 15 May 2025, 20:36 IST
- Board meeting
- 15 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 15 May 2025, 20:36 IST
- Board meeting
- 15 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE